182 related articles for article (PubMed ID: 1696762)
1. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland.
O'Malley FP; Grignon DJ; Shum DT
Virchows Arch A Pathol Anat Histopathol; 1990; 417(3):191-6. PubMed ID: 1696762
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
3. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.
Wojno KJ; Epstein JI
Am J Surg Pathol; 1995 Mar; 19(3):251-60. PubMed ID: 7532918
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate.
Shah IA; Schlageter MO; Stinnett P; Lechago J
Mod Pathol; 1991 Mar; 4(2):220-4. PubMed ID: 1710806
[TBL] [Abstract][Full Text] [Related]
5. Minimal adenocarcinoma in prostate needle biopsy tissue.
Thorson P; Humphrey PA
Am J Clin Pathol; 2000 Dec; 114(6):896-909. PubMed ID: 11338479
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of prostate carcinoma on biopsy specimens improved by basal-cell-specific anti-cytokeratin antibody (34 beta E12).
Freibauer C
Wien Klin Wochenschr; 1998 Sep; 110(17):608-11. PubMed ID: 9816630
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing atrophy and high-grade prostatic intraepithelial neoplasia from prostatic adenocarcinoma with and without previous adjuvant hormone therapy with the aid of cytokeratin 5/6.
Abrahams NA; Bostwick DG; Ormsby AH; Qian J; Brainard JA
Am J Clin Pathol; 2003 Sep; 120(3):368-76. PubMed ID: 14502799
[TBL] [Abstract][Full Text] [Related]
8. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.
Oliai BR; Kahane H; Epstein JI
Am J Surg Pathol; 2002 Sep; 26(9):1151-60. PubMed ID: 12218571
[TBL] [Abstract][Full Text] [Related]
9. [The application of high molecular weight cytokeratin in differential diagnosis of prostate adenocarcinoma].
Kong X; Deng F; Wang J
Zhonghua Bing Li Xue Za Zhi; 1996 Aug; 25(4):199-201. PubMed ID: 9275650
[TBL] [Abstract][Full Text] [Related]
10. Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma.
Googe PB; McGinley KM; Fitzgibbon JF
Am J Clin Pathol; 1997 Feb; 107(2):219-23. PubMed ID: 9024071
[TBL] [Abstract][Full Text] [Related]
11. Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma.
Cheville JC; Bostwick DG
Am J Surg Pathol; 1995 Sep; 19(9):1068-76. PubMed ID: 7544958
[TBL] [Abstract][Full Text] [Related]
12. Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.
Turhan OI; Aydin NE; Sariyüce O; Ozkan S
Int Urol Nephrol; 1998; 30(6):731-44. PubMed ID: 10195869
[TBL] [Abstract][Full Text] [Related]
13. Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate.
Shin M; Fujita MQ; Yasunaga Y; Miki T; Okuyama A; Aozasa K
Int J Urol; 1998 May; 5(3):237-42. PubMed ID: 9624554
[TBL] [Abstract][Full Text] [Related]
14. [Benign microglandular prostate lesions. Diagnostic criteria na differential diagnosis].
Bonkhoff H; Remberger K
Pathologe; 1998 Jan; 19(1):1-11. PubMed ID: 9541937
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical analysis with anti-cytokeratin antibody in the prostatic epithelium].
Yamanaka Y; Ishida H; Okada K; Nemoto N
Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):545-53. PubMed ID: 11517564
[TBL] [Abstract][Full Text] [Related]
16. Acidic mucin in the prostate: can it differentiate adenosis from adenocarcinoma?
Epstein JI; Fynheer J
Hum Pathol; 1992 Dec; 23(12):1321-5. PubMed ID: 1281806
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Difficulties With Atrophy, Atypical Adenomatous Hyperplasia, and Atypical Small Acinar Proliferation: A Systematic Review of Current Literature.
Kowalewski A; Szylberg Ł; Skórczewska A; Marszałek A
Clin Genitourin Cancer; 2016 Oct; 14(5):361-365. PubMed ID: 26992486
[TBL] [Abstract][Full Text] [Related]
18. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
19. Small-acinar patterns in the prostate gland with emphasis on atypical adenomatous hyperplasia and small-acinar carcinoma.
Srigley JR
Semin Diagn Pathol; 1988 Aug; 5(3):254-72. PubMed ID: 2459751
[TBL] [Abstract][Full Text] [Related]
20. The differential diagnosis of prostatic carcinoma. Its distinction from premalignant and pseudocarcinomatous lesions of the prostate gland.
Jones EC; Young RH
Am J Clin Pathol; 1994 Jan; 101(1):48-64. PubMed ID: 7506479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
